CP3R and AJH’s Performance for Non-Small Cell Lung Cancer
SURGERY IS NOT FIRST COURSE OF TREATMENT FOR NON-SMALL CELL LUNG CANCER THAT HAS NOT SPREAD TO DISTANT ORGANS OR AREAS
Surgery is not First Course of Treatment for Non-Small Cell Lung Cancer That Has Not Spread to Distant Organs or Areas
This quality measure examines whether surgery was used within the ﬁrst course of treatment for Non-Small Cell Lung Cancer that has not spread to other organs. Abington – Jefferson Health’s compliance rate of 90.9% is below the CoC standard rate of 92.7%.
CHEMOTHERAPY IN LYMPH NODE POSITIVE NON-SMALL CELL LUNG CANCER
Chemotherapy in Lymph Node Positive Non-Small Cell Lung Cancer
Chemotherapy administered within four months to day preoperatively or day of surgery to six months postoperatively, or it is considered for surgically resected cases with pathologic, lymph node positive Non-Small Cell Lung Cancer. Abington – Jefferson Health’s compliance is 100% compared to the CoC average of 92.3%.